MGX (Metagenomi) EV-to-EBITDA : 1.45 (As of May. 19, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Metagenomi EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Metagenomi's enterprise value is $-119.48 Mil. Metagenomi's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-82.20 Mil. Therefore, Metagenomi's EV-to-EBITDA for today is 1.45.

The historical rank and industry rank for Metagenomi's EV-to-EBITDA or its related term are showing as below:

MGX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.16 Med: 1.53 Max: 2.4
Current: 1.45

During the past 4 years, the highest EV-to-EBITDA of Metagenomi was 2.40. The lowest was -3.16. And the median was 1.53.

MGX's EV-to-EBITDA is ranked better than
60.69% of 496 companies
in the Biotechnology industry
Industry Median: 7.955 vs MGX: 1.45

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-19), Metagenomi's stock price is $1.71. Metagenomi's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-2.110. Therefore, Metagenomi's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).

Metagenomi EV-to-EBITDA Historical Data

The historical data trend for Metagenomi's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Metagenomi EV-to-EBITDA Chart

Metagenomi Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

EV-to-EBITDA

0.81

Metagenomi Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBITDA	Get a 7-Day Free Trial							-1.36	1.19	1.77	0.81	1.59

Competitive Comparison of Metagenomi's EV-to-EBITDA

For the Biotechnology subindustry, Metagenomi's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Metagenomi's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Metagenomi's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Metagenomi's EV-to-EBITDA falls into.

Save Embed

;

Save Embed

;

Metagenomi EV-to-EBITDA Calculation

Metagenomi's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	-119.478	/	-82.197
	=	1.45

Metagenomi's current Enterprise Value is $-119.48 Mil.
Metagenomi's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-82.20 Mil.

Metagenomi (NAS:MGX) EV-to-EBITDA Explanation

Metagenomi's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	1.71	/	-2.110
	=	At Loss

Metagenomi's share price for today is $1.71.
Metagenomi's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.110.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Metagenomi EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Metagenomi's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Metagenomi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Metagenomi Inc (NAS:MGX) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608

Website

https://metagenomi.co

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.